After success with J&J, Legend strikes another license agreement, this one with Swiss pharma Novartis around CAR-T therapies.
Novartis Enters into Deal with Legend Biotech for $100 Million Upfront Read More »
Pennsylvania-based Aclaris Therapeutics will stop development of zunsemetinib after it failed to meet the primary endpoint in a Phase II study for rheumatoid arthritis.
Aclaris’ Stock Crashes after Lead Asset Fails Mid-Stage Trial Read More »
The data confirmed a cardiovascular benefit for heart patients and showed the drug could help pre-diabetic patients control their blood sugar.
Wegovy study details revive debate over GLP-1 impact on devices Read More »
The company lowered its 2023 sales and earnings forecasts in response to the incident, which took some of its distribution systems offline.
Henry Schein says customer data breached in cyber incident Read More »
The buyouts come after the Boston-based nonprofit health system faced scrutiny from state regulators over spending.
Mass General Brigham offers buyouts to workers in its digital unit Read More »
Engagement with online medical records increased during the pandemic, but fewer Black and Hispanic patients accessed electronic health information compared with White patients.
Patient portal access spikes during pandemic, but disparities persist, study finds Read More »
The UK-based nanomedicine biotech, previously known as SomaServe, has closed its Series A with some significant biopharma names attached.
Lilly, UCB-Backed ViaNautis Scores $25M for Genetic Nanomedicines Read More »
The UK-based nanomedicine biotech, previously known as SomaServe, has closed its Series A with some significant biopharma names attached.
At its highest dose level of 608 mg, lepodisiran reduced lipoprotein(a) levels by a median of 94% after 48 weeks.
Lilly Notches Second Cholesterol Win with RNA Silencer Read More »
When given at potentially therapeutic doses, Verve’s base editor led to strong reductions in LDL cholesterol and PCSK9 levels in patients with heterozygous familial hypercholesterolemia.
Verve’s Gene Editor Cuts Cholesterol in First-in-Human HeFH Trial Read More »
